Multiple Cox proportional hazards models (adjusted for covariates identified by Davidson et al12) for the association between mPERR category at 2 years post biopsy and ESRD or death and renal insufficiency during follow-up
| Study variable | Event (n) | Censored (n) | HR (95% CI range) | P value |
| Association between mPERR status and ESRD* or death | ||||
| mPERR at 2 years post biopsy | 18 | 155 | 0.33 (0.13 to 0.87) | 0.0255 |
| SDI | 18 | 155 | 1.13 (0.99 to 1.29) | 0.0806 |
| Hypertension† | 18 | 155 | 4.33 (0.57 to 32.73) | 0.1552 |
| Association between mPERR status and chronic renal insufficiency‡ | ||||
| mPERR at 2 years post biopsy | 43 | 130 | 0.26 (0.14 to 0.47) | <0.0001 |
| Age at biopsy date (baseline) | 43 | 130 | 1.04 (1.02 to 1.06) | 0.0006 |
| Hydroxychloroquine use from baseline to 2 years post biopsy | 43 | 130 | 0.50 (0.27 to 0.93) | 0.0277 |
*Clinical assessment of ESRD regardless of dialysis or transplant.
†Between baseline and 2 years post biopsy.
‡New kidney damage OR new occurrence of GFR <60 mL/min/1.73 m2 on at least two consecutive measurement occasions ≥3 months apart.
ACR, American College of Rheumatology; CI, confidence interval; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HR, hazard ratio; mPERR, modified primary efficacy renal response; SDI, SLICC/ACR Damage Index; SLICC, Systemic Lupus International Collaborating Clinic.